BridgeMD
A bicentric, randomized, double blind, placebo-controlled pilot study to evaluate the efficacy and safety of satralizumab in FSHD1
EU CTIS ID: 2023-504507-81-00
What this study is testing
To evaluate the efficacy and safety of satralizumab compared with placebo in patients with FSHD1
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Capable of understanding the written informed consent, and providing signed, dated, and witnessed written informed consent
- Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures
- For female patients of childbearing potential: use adequate contraception during the treatment period and/or until tratment discontinuation
- Male or female subjects between the ages of 18 and 65 years, inclusive
- Patient affiliated to a European social security system (Nice center only)
- Genetically confirmed diagnosis of typical FSHD1 with 1 to 9 D4Z4 repeats via assessment of the size of the D4Z4 array on chromosome 4. Genetic confirmation must be obtained before the subject screening assessments, including MRI, and before the baseline. Genetic confirmation can come from previous testing if verified with appropriate documentation from an accredited laboratory. Due to stable transmission of repeat sizes within families, subjects with a clinical diagnosis of FSHD who have a first-degree relative with a genetically confirmed diagnosis of FSHD1 may be entered into the study for screening assessments, including MRI
You likely can't join if
- History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject
- Positive screen for hepatitis B surface antigen (HbsAg), antibody (anti-HbS), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV-1/HIV-2)
- Acute or chronic history of liver disease
- Abnormal laboratory results with : White blood cells (WBC) < 3.0x 10^9/L ; Absolute Neutrophils Counts (ANC) < 2.0x 10^9/L ; Platelet count < 10x 10^4/µl ; Absolute lymphocyte count (ALC) < 0.8x 10^3/µl ; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 1.5 times the upper limit of normal (ULN)
- Severe renal impairment (defined as a glomerular filtration rate of <30mL/min/1.73m²)
- Vaccination with live or live-attenuated vaccines within the 6 weeks prior to randomization
See the full eligibility criteria
Who can join
- Capable of understanding the written informed consent, and providing signed, dated, and witnessed written informed consent
- Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures
- For female patients of childbearing potential: use adequate contraception during the treatment period and/or until tratment discontinuation
- Male or female subjects between the ages of 18 and 65 years, inclusive
- Patient affiliated to a European social security system (Nice center only)
- Genetically confirmed diagnosis of typical FSHD1 with 1 to 9 D4Z4 repeats via assessment of the size of the D4Z4 array on chromosome 4. Genetic confirmation must be obtained before the subject screening assessments, including MRI, and before the baseline. Genetic confirmation can come from previous testing if verified with appropriate documentation from an accredited laboratory. Due to stable transmission of repeat sizes within families, subjects with a clinical diagnosis of FSHD who have a first-degree relative with a genetically confirmed diagnosis of FSHD1 may be entered into the study for screening assessments, including MRI
- Clinical severity score of 2 to 4 (RICCI score; range 0-5), inclusive
- 6Patients with a body weight of below or equal 100 kg
- On initial whole-body MRI, subjects with: a. At least one muscle in lower limbs showing STIR or T2-Dixon positive signal ; b. Evidence of muscle fat replacement such that the total lean volume of muscles with an intermediate fat replacement (i.e. muscle with at least 10% of Muscle Fat Infiltration and no more than 50% of Muscle Fat Fraction) is at least 500 ml if there is only one intermediate muscle or 250 ml if there is more than one intermediate muscle.
- Subjects able to walk without support
- Willing to maintain same level of exercise (frequency and intensity) during the study
What rules you out
- History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject
- Positive screen for hepatitis B surface antigen (HbsAg), antibody (anti-HbS), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV-1/HIV-2)
- Acute or chronic history of liver disease
- Abnormal laboratory results with : White blood cells (WBC) < 3.0x 10^9/L ; Absolute Neutrophils Counts (ANC) < 2.0x 10^9/L ; Platelet count < 10x 10^4/µl ; Absolute lymphocyte count (ALC) < 0.8x 10^3/µl ; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 1.5 times the upper limit of normal (ULN)
- Severe renal impairment (defined as a glomerular filtration rate of <30mL/min/1.73m²)
- Vaccination with live or live-attenuated vaccines within the 6 weeks prior to randomization
- Pregnancy or lactation
- For patients of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception (physical barrier [patient or partner] in conjunction with a spermicidal product, contraceptive pill, patch, injectable, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug
- Any current mental condition (psychiatric disorder, senility, or dementia) that, in the opinion of the investigator, may affect study compliance or prevent understanding of the aims, investigational procedures, or possible consequences of the study
- Use of another investigational product within 6 months or 5 half-lives (whichever is longer), or according to local regulations, or currently participating in a prospective study with an investigational product, whether it concerns an experimental drug or a medical device. Note: concurrent participation in natural history studies (non-drug, non-device studies) may be acceptable if confirmed in writing by the sponsor. In the case of patients treated with Losmapimod, the wash out period will be 5 half-lives.
- Any prior treatment with any agent targeting the IL-6 inhibition pathway (e.g. tocilizumab, sarilumab), alemtuzumab treatment, total body irradiation, or bone marrow transplantation; treatment in the past 24 weeks with an anti-B-lymphocyte antigen CD20 (e.g. rituximab, ocrelizumab), eculizumab, anti-B-lymphocyte stimulator, or any other multiple sclerosis disease-modifying treatment; treatment in the past 2 years with an anti-T-cell surface glycoprotein CD4, cladribine, cyclophosphamide, or mitoxantrone; or treatment with any other investigational drug within 3 months prior to baseline
- History of malignancy within the last 5 years
- Subject, or close relative of the subject, is the investigator or a subinvestigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site
- Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code
- Subjects who are on drug(s) or supplements that may affect muscle function
- Orthopedic conditions, such as unresolved fracture or arthrosis, interfering or precluding testing of muscle function
- Contraindication to muscle MRI as per clinic standard practice
- Articular contracture limiting movements, scapular fixation or other surgeries, preceding or planned
- Any known hypersensitivity to satralizumab or any of its components and/or history of severe allergic reaction to a biologic agent (e.g., shock, anaphylactic reactions)
- Evidence of latent or active tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection for at least 4 weeks prior to enrollment), active opportunistic or life-threatening infections
- History of diverticulitis or concurrent severe GI disorders (such as symptomatic diverticulosis) that, in the investigator’s opinion, may lead to increased risk of complications such as GI perforation. Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit or oral anti-infective agents within 2 weeks prior to baseline visit (Visit 1, week 0)
The study team makes the final eligibility decision.
Where it's taking place
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.